Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Subscribe To Our Newsletter & Stay Updated
